Document Detail


Primary Cells and Stem Cells in Drug Discovery: Emerging Tools for High-Throughput Screening.
MedLine Citation:
PMID:  21186936     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Many drug discovery screening programs employ immortalized cells, recombinantly engineered to express a defined molecular target. Several technologies are now emerging that render it feasible to employ more physiologically, and clinically relevant, cell phenotypes. Consequently, numerous approaches use primary cells, which retain many functions seen in vivo, as well as endogenously expressing the target of interest. Furthermore, stem cells, of either embryonic or adult origin, as well as those derived from differentiated cells, are now finding a place in drug discovery. Collectively, these cells are expanding the utility of authentic human cells, either as screening tools or as therapeutics, as well as providing cells derived directly from patients. Nonetheless, the growing use of phenotypically relevant cells (including primary cells or stem cells) is not without technical difficulties, particularly when their envisioned use lies in high-throughput screening (HTS) protocols. In particular, the limited availability of homogeneous primary or stem cell populations for HTS mandates that novel technologies be developed to accelerate their adoption. These technologies include detection of responses with very few cells as well as protocols to generate cell lines in abundant, homogeneous populations. In parallel, the growing use of changes in cell phenotype as the assay readout is driving greater use of high-throughput imaging techniques in screening. Taken together, the greater availability of novel primary and stem cell phenotypes as well as new detection technologies is heralding a new era of cellular screening. This convergence offers unique opportunities to identify drug candidates for disorders at which few therapeutics are presently available.
Authors:
Richard Eglen; Terry Reisine
Related Documents :
19182206 - Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflame...
789096 - A plaque assay for all cells secreting ig of a given type or class.
7190976 - Differences in pattern and level of plasminogen activator production between a cloned c...
21389986 - Hedgehog/wnt feedback supports regenerative proliferation of epithelial stem cells in b...
9544986 - Cell-specific inhibition of retinoic acid receptor-alpha silencing by the af2/tau c act...
8195976 - The effect of a light-cured periodontal dressing material on hela cells and fibroblasts...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-12-27
Journal Detail:
Title:  Assay and drug development technologies     Volume:  -     ISSN:  1557-8127     ISO Abbreviation:  -     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101151468     Medline TA:  Assay Drug Dev Technol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1 Bio-discovery, PerkinElmer , Waltham, Massachusetts.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Desensitization to media violence: Links with habitual media violence exposure, aggressive cognition...
Next Document:  Quantification of hormone sensitive lipase phosphorylation and colocalization with lipid droplets in...